337 related articles for article (PubMed ID: 19906198)
1. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
2. A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells.
Michaelsen TE; Thommesen JE; Ihle O; Gregers TF; Sandin RH; Brekke OH; Sandlie I
Eur J Immunol; 2006 Jan; 36(1):129-38. PubMed ID: 16323243
[TBL] [Abstract][Full Text] [Related]
3. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
4. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
5. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
6. Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines.
Vestrheim AC; Moen A; Egge-Jacobsen W; Bratlie DB; Michaelsen TE
Scand J Immunol; 2013 May; 77(5):419-28. PubMed ID: 23488770
[TBL] [Abstract][Full Text] [Related]
7. Activation of complement by an IgG molecule without a genetic hinge.
Brekke OH; Michaelsen TE; Sandin R; Sandlie I
Nature; 1993 Jun; 363(6430):628-30. PubMed ID: 8510754
[TBL] [Abstract][Full Text] [Related]
8. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
Bindon CI; Hale G; Brüggemann M; Waldmann H
J Exp Med; 1988 Jul; 168(1):127-42. PubMed ID: 3260935
[TBL] [Abstract][Full Text] [Related]
9. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.
Lohse S; Peipp M; Beyer T; Valerius T; Dechant M
Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):303-12. PubMed ID: 20508996
[TBL] [Abstract][Full Text] [Related]
10. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
[TBL] [Abstract][Full Text] [Related]
11. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
12. Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation.
Saethre M; Lea T; Borgen MS; Fiane AE; Michaelsen TE; Thorsby E; Haraldsen G; Mollnes TE
Xenotransplantation; 2006 May; 13(3):215-23. PubMed ID: 16756564
[TBL] [Abstract][Full Text] [Related]
13. C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids.
Sandlie I; Aase A; Westby C; Michaelsen TE
Eur J Immunol; 1989 Sep; 19(9):1599-603. PubMed ID: 2792180
[TBL] [Abstract][Full Text] [Related]
14. Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis.
Brekke OH; Michaelsen TE; Aase A; Sandin RH; Sandlie I
Eur J Immunol; 1994 Oct; 24(10):2542-7. PubMed ID: 7925582
[TBL] [Abstract][Full Text] [Related]
15. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration.
Michaelsen TE; Garred P; Aase A
Eur J Immunol; 1991 Jan; 21(1):11-6. PubMed ID: 1703960
[TBL] [Abstract][Full Text] [Related]
16. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge.
Norderhaug L; Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
Eur J Immunol; 1991 Oct; 21(10):2379-84. PubMed ID: 1915551
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies.
Hughes-Jones NC; Gorick BD; Howard JC
Eur J Immunol; 1983 Aug; 13(8):635-41. PubMed ID: 6603980
[TBL] [Abstract][Full Text] [Related]
18. Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52.
Redpath S; Michaelsen T; Sandlie I; Clark MR
Immunology; 1998 Apr; 93(4):595-600. PubMed ID: 9659234
[TBL] [Abstract][Full Text] [Related]
19. The binding site for C1q on IgG.
Duncan AR; Winter G
Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
[TBL] [Abstract][Full Text] [Related]
20. Species specificity in the binding of IgG to macrophages.
Leslie RG; Niemetz AH
Immunology; 1979 Aug; 37(4):835-40. PubMed ID: 500129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
